JP2008500987A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008500987A5 JP2008500987A5 JP2007513836A JP2007513836A JP2008500987A5 JP 2008500987 A5 JP2008500987 A5 JP 2008500987A5 JP 2007513836 A JP2007513836 A JP 2007513836A JP 2007513836 A JP2007513836 A JP 2007513836A JP 2008500987 A5 JP2008500987 A5 JP 2008500987A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrocortisone
- propionate
- betamethasone
- methylprednisolone
- dexamethasone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 vitorterol Chemical compound 0.000 description 6
- UREBDLICKHMUKA-DVTGEIKXSA-N Betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- BPZSYCZIITTYBL-YJYMSZOUSA-N Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N Methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
- FNPXMHRZILFCKX-KAJVQRHHSA-N Prednicarbate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O FNPXMHRZILFCKX-KAJVQRHHSA-N 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960002794 prednicarbate Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- MYZDPUZXMFCPMU-LRIWMWCYSA-N (6R,8S,9R,10S,11S,13S,14S,17R)-2-bromo-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1C(Br)=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@@H](F)C2=C1 MYZDPUZXMFCPMU-LRIWMWCYSA-N 0.000 description 1
- DXEXNWDGDYUITL-FXSSSKFRSA-N (8S,9R,10S,11S,13S,14S,17R)-17-ethylsulfanyl-9-fluoro-11-hydroxy-10,13-dimethyl-17-methylsulfanyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](SC)(SCC)[C@@]1(C)C[C@@H]2O DXEXNWDGDYUITL-FXSSSKFRSA-N 0.000 description 1
- DBCKRBGYGMVSTI-UHFFFAOYSA-N 2-oxo-7-[2-[2-[3-(2-phenylethoxy)propylsulfonyl]ethylazaniumyl]ethyl]-3H-1,3-benzothiazol-4-olate Chemical compound C1=2SC(=O)NC=2C(O)=CC=C1CCNCCS(=O)(=O)CCCOCCC1=CC=CC=C1 DBCKRBGYGMVSTI-UHFFFAOYSA-N 0.000 description 1
- RTLJQOLVPIGICL-UHFFFAOYSA-N 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(methylsulfonylmethyl)phenol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CS(C)(=O)=O)=C1 RTLJQOLVPIGICL-UHFFFAOYSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N 4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}benzene-1,2-diol Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- XBGQGAPUUJJOTA-KWLUMGGGSA-N 4B52439Y33 Chemical compound O.C([C@@H]1C2)C3=CC=CC=C3C[C@@]1(C(=O)CO)[C@]1(C)[C@@H]2[C@H](CCC=2[C@@]3(C=CC(=O)C=2)C)[C@]3(F)[C@@H](O)C1 XBGQGAPUUJJOTA-KWLUMGGGSA-N 0.000 description 1
- 229940022663 Acetate Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N Bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 229940092703 Beclomethasone Dipropionate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N Betamethasone 17-valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N Bricaril Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- JBRBWHCVRGURBA-UHFFFAOYSA-N Broxaterol Chemical compound CC(C)(C)NCC(O)C1=CC(Br)=NO1 JBRBWHCVRGURBA-UHFFFAOYSA-N 0.000 description 1
- 229950008847 Broxaterol Drugs 0.000 description 1
- 229960004436 Budesonide Drugs 0.000 description 1
- VOVIALXJUBGFJZ-VXKMTNQYSA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-VXKMTNQYSA-N 0.000 description 1
- KEMXXQOFIRIICG-UHFFFAOYSA-N Carbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(NC(N)=O)=C1 KEMXXQOFIRIICG-UHFFFAOYSA-N 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N Clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- RYBJORHCUPVNMB-UHFFFAOYSA-N Dopexamine Chemical compound C1=C(O)C(O)=CC=C1CCNCCCCCCNCCC1=CC=CC=C1 RYBJORHCUPVNMB-UHFFFAOYSA-N 0.000 description 1
- LSLYOANBFKQKPT-UHFFFAOYSA-N Fenoterol Chemical compound C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 LSLYOANBFKQKPT-UHFFFAOYSA-N 0.000 description 1
- XSFJVAJPIHIPKU-XWCQMRHXSA-N Flunisolide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O XSFJVAJPIHIPKU-XWCQMRHXSA-N 0.000 description 1
- 229960001347 Fluocinolone Acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N Fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N Fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 1
- GGXMRPUKBWXVHE-MIHLVHIWSA-N Halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 description 1
- OXLZNBCNGJWPRV-UHFFFAOYSA-N Hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 description 1
- HHZQLQREDATOBM-CODXZCKSSA-M Hydrocortisone Sodium Succinate Chemical compound [Na+].O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 HHZQLQREDATOBM-CODXZCKSSA-M 0.000 description 1
- FOGXJPFPZOHSQS-AYVLZSQQSA-N Hydrocortisone butyrate propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O FOGXJPFPZOHSQS-AYVLZSQQSA-N 0.000 description 1
- 229960001401 Hydrocortisone sodium succinate Drugs 0.000 description 1
- 229950002451 Ibuterol Drugs 0.000 description 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N Indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N Levosalbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- JSJCTEKTBOKRST-UHFFFAOYSA-N Mabuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(C(F)(F)F)=C1 JSJCTEKTBOKRST-UHFFFAOYSA-N 0.000 description 1
- 229950004407 Mabuterol Drugs 0.000 description 1
- DALKLAYLIPSCQL-YPYQNWSCSA-N Methylprednisolone aceponate Chemical compound C1([C@@H](C)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]2(C)C[C@@H]1O DALKLAYLIPSCQL-YPYQNWSCSA-N 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N Mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- BMKINZUHKYLSKI-DQEYMECFSA-N N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[2-[4-[[(2R)-2-hydroxy-2-phenylethyl]amino]phenyl]ethylamino]ethyl]phenyl]formamide Chemical compound C1([C@@H](O)CNC2=CC=C(C=C2)CCNC[C@H](O)C=2C=C(NC=O)C(O)=CC=2)=CC=CC=C1 BMKINZUHKYLSKI-DQEYMECFSA-N 0.000 description 1
- 229950005486 Naflocort Drugs 0.000 description 1
- 229950004349 Nolomirole Drugs 0.000 description 1
- LMOINURANNBYCM-UHFFFAOYSA-N Orciprenaline Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 description 1
- 229950010765 Pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960002288 Procaterol Drugs 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N Procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N Reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- 229960001634 Ritodrine Drugs 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N Ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N Salbutamol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 229950005229 Sibenadet Drugs 0.000 description 1
- 229950007862 Sulfonterol Drugs 0.000 description 1
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 1
- 229960000195 Terbutaline Drugs 0.000 description 1
- 229950001669 Tipredane Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N Triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960002117 Triamcinolone Acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N Triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- YREYLAVBNPACJM-UHFFFAOYSA-N Tulobuterol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 1
- BDSYKGHYMJNPAB-LICBFIPMSA-N [(6S,8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 description 1
- VXOWJCTXWVWLLC-REGDIAEZSA-N [(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-(2-propanoyloxyacetyl)-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O VXOWJCTXWVWLLC-REGDIAEZSA-N 0.000 description 1
- MFBMYAOAMQLLPK-FZNHGJLXSA-N [(8S,9S,10R,11S,13S,14S,17R)-17-(2-acetyloxyacetyl)-11-hydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] propanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]1(C)C[C@@H]2O MFBMYAOAMQLLPK-FZNHGJLXSA-N 0.000 description 1
- WDPYZTKOEFDTCU-WDJQFAPHSA-N [2-[(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] hexadecanoate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CCCCCCCCCCCCCCC)(O)[C@@]1(C)C[C@@H]2O WDPYZTKOEFDTCU-WDJQFAPHSA-N 0.000 description 1
- SBQAKZYUNWNIRL-WIPKXTQKSA-N [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienoate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)/C=C(C)/CC/C=C(C)/CCC=C(C)C)(O)[C@@]1(C)C[C@@H]2O SBQAKZYUNWNIRL-WIPKXTQKSA-N 0.000 description 1
- WKHOPHIMYDJVSA-UHFFFAOYSA-N [3-[2-(tert-butylamino)-1-hydroxyethyl]-5-(2-methylpropanoyloxy)phenyl] 2-methylpropanoate Chemical compound CC(C)C(=O)OC1=CC(OC(=O)C(C)C)=CC(C(O)CNC(C)(C)C)=C1 WKHOPHIMYDJVSA-UHFFFAOYSA-N 0.000 description 1
- OMMYLOLVPCCZQZ-UHFFFAOYSA-N [6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate Chemical compound C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1CC(NC)CC2 OMMYLOLVPCCZQZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960004229 alclometasone dipropionate Drugs 0.000 description 1
- DJHCCTTVDRAMEH-DUUJBDRPSA-N alclometasone dipropionate Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DJHCCTTVDRAMEH-DUUJBDRPSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 229950008408 betamethasone butyrate propionate Drugs 0.000 description 1
- 229960001386 carbuterol Drugs 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229950000812 dexamethasone palmitate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical class [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 229960001857 dopexamine Drugs 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940048498 halobetasol propionate Drugs 0.000 description 1
- 229960002475 halometasone Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960002453 hydrocortisone aceponate Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229960002846 hydrocortisone probutate Drugs 0.000 description 1
- 229950006240 hydrocortisone succinate Drugs 0.000 description 1
- 229960004078 indacaterol Drugs 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 229950008204 levosalbutamol Drugs 0.000 description 1
- 229960003744 loteprednol etabonate Drugs 0.000 description 1
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 description 1
- 229960002037 methylprednisolone aceponate Drugs 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- 229960002657 orciprenaline Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 229950011084 prednisolone farnesylate Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 229960000859 tulobuterol Drugs 0.000 description 1
- 229950008396 ulobetasol propionate Drugs 0.000 description 1
Description
本発明の組合せ剤において使用するのに好ましいβ２−アゴニストは：アルフォルモテロール、バンブテロール、ビトルテロール、ブロキサテロール(broxaterol)、カルブテロール(carbuterol)、クレンブテロール、ドペキサミン、フェノテロール、フォルモテロール、ヘキソプレナリン、イブテロール(ibuterol)、イソプレナリン、レボサルブタモール、マブテロール、メルアドリン、ノロミロール(nolomirole)、オルシプレナリン、ピルブテロール、プロカテロール、(Ｒ,Ｒ)−フォルモテロール、レプロテロール、リトドリン、リモテロール(rimoterol)、サルブタモール、サルメテロール、シベナデット(sibenadet)、スルフォンテロール(sulfonterol)、テルブタリン、ツロブテロール、ＧＳＫ−５９７９０１、ＧＳＫ−１５９７９７、ＫＵＬ−１２４８、ＴＡ−２００５およびＱＡＢ−１４９(所望によりそれらのラセミ体、それらのエナンチオマー、それらのジアステレオマー、およびそれらの混合物の形、ならびに所望によりそれらの薬理学的に適合性の酸付加塩の形である)である。
Ｍ３−アンタゴニストおよびβ２−アゴニストと組み合わせることができる適当なコルチコステロイドおよびグルココルチコイドの例は、プレドニゾロン、メチルプレドニゾロン、デキサメサゾン、ナフロコート(naflocort)、デフラザコート、ハロプレドン酢酸塩、ブデソニド、ベクロメタゾン二プロピオン酸塩、ヒドロコルチゾン、トリアムシノロンアセトニド、フルオシノロンアセトニド、フルオシノニド、クロコルトロンピバル酸塩、メチルプレドニゾロンアセポナート、デキサメサゾンパルミチン酸塩(palmitoate)、チプレダン(tipredane)、ヒドロコルチゾンアセポナート、プレドニカルベート(prednicarbate)、アルクロメタゾン(alclometasone)二プロピオン酸塩、ハロメタゾン、メチルプレドニゾロンスレプタネート(suleptanate)、モメタゾンフロ酸塩、リメキソロン、プレドニゾロンファルネシル酸塩、シクレソニド、デプロドンプロピオン酸塩、フルチカゾンプロピオン酸塩、ハロベタゾールプロピオン酸塩、ロテプレドノールエタボン酸塩、ベタメタゾン酪酸塩プロピオン酸塩、フルニソリド、プレドニゾン、デキサメサゾンリン酸ナトリウム塩、トリアムシノロン、ベタメタゾン１７−吉草酸塩、ベタメタゾン、ベタメタゾン二プロピオン酸塩、ヒドロコルチゾン酢酸塩、ヒドロコルチゾンナトリウムコハク酸塩、プレドニゾロンリン酸ナトリウム塩およびヒドロコルチゾンプロブテート(probutate)である。
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP200401312 | 2004-05-31 | ||
| ES200401312A ES2257152B1 (es) | 2004-05-31 | 2004-05-31 | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| EP2005001969 | 2005-02-24 | ||
| EPPCT/EP2005/001969 | 2005-02-24 | ||
| GBPCT/GB2005/000722 | 2005-02-25 | ||
| GB2005000722 | 2005-02-25 | ||
| GB2005000740 | 2005-02-25 | ||
| GBPCT/GB2005/000740 | 2005-02-25 | ||
| PCT/EP2005/005837 WO2005115463A1 (en) | 2004-05-31 | 2005-05-31 | Combinations comprising antimuscarinic agents and beta-adrenergic agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008500987A JP2008500987A (ja) | 2008-01-17 |
| JP2008500987A5 true JP2008500987A5 (ja) | 2008-07-17 |
| JP4966192B2 JP4966192B2 (ja) | 2012-07-04 |
Family
ID=34956036
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007513836A Expired - Fee Related JP4966192B2 (ja) | 2004-05-31 | 2005-05-31 | 抗ムスカリン剤およびβ−アドレナリンアゴニストを含む組合せ剤 |
| JP2007513835A Expired - Fee Related JP5133054B2 (ja) | 2004-05-31 | 2005-05-31 | 抗ムスカリン剤およびｐｄｅ４阻害剤を含む組合せ剤 |
| JP2007513837A Expired - Fee Related JP5049120B2 (ja) | 2004-05-31 | 2005-05-31 | 抗ムスカリン剤およびコルチコステロイドを含む組合せ剤 |
| JP2007513839A Expired - Fee Related JP5032984B2 (ja) | 2004-05-31 | 2005-05-31 | 抗ムスカリン剤およびコルチコステロイドを含む組合せ剤 |
| JP2007513838A Expired - Fee Related JP5107701B2 (ja) | 2004-05-31 | 2005-05-31 | 抗ムスカリン剤およびｐｄｅ４阻害剤を含む組合せ剤 |
| JP2006508319A Active JP4928258B2 (ja) | 2004-05-31 | 2005-05-31 | 抗ムスカリン剤およびベータ−アドレナリンアゴニストを含む組み合わせ |
| JP2011215066A Pending JP2012012407A (ja) | 2004-05-31 | 2011-09-29 | 抗ムスカリン剤およびベータ−アドレナリンアゴニストを含む組み合わせ |
| JP2012152733A Expired - Fee Related JP5538485B2 (ja) | 2004-05-31 | 2012-07-06 | 抗ムスカリン剤およびｐｄｅ４阻害剤を含む組合せ剤 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007513835A Expired - Fee Related JP5133054B2 (ja) | 2004-05-31 | 2005-05-31 | 抗ムスカリン剤およびｐｄｅ４阻害剤を含む組合せ剤 |
| JP2007513837A Expired - Fee Related JP5049120B2 (ja) | 2004-05-31 | 2005-05-31 | 抗ムスカリン剤およびコルチコステロイドを含む組合せ剤 |
| JP2007513839A Expired - Fee Related JP5032984B2 (ja) | 2004-05-31 | 2005-05-31 | 抗ムスカリン剤およびコルチコステロイドを含む組合せ剤 |
| JP2007513838A Expired - Fee Related JP5107701B2 (ja) | 2004-05-31 | 2005-05-31 | 抗ムスカリン剤およびｐｄｅ４阻害剤を含む組合せ剤 |
| JP2006508319A Active JP4928258B2 (ja) | 2004-05-31 | 2005-05-31 | 抗ムスカリン剤およびベータ−アドレナリンアゴニストを含む組み合わせ |
| JP2011215066A Pending JP2012012407A (ja) | 2004-05-31 | 2011-09-29 | 抗ムスカリン剤およびベータ−アドレナリンアゴニストを含む組み合わせ |
| JP2012152733A Expired - Fee Related JP5538485B2 (ja) | 2004-05-31 | 2012-07-06 | 抗ムスカリン剤およびｐｄｅ４阻害剤を含む組合せ剤 |
Country Status (46)
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100471016B1 (ko) * | 1996-08-07 | 2005-07-12 | 스미또모 가가꾸 가부시키가이샤 | 살충성에어로졸조성물및이를제조하기위한살충조성물 |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US20050026948A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| BRPI0413054A (pt) * | 2003-07-29 | 2006-10-17 | Boehringer Ingelheim Int | combinação de um anticolinérgico e um esteróide e seu uso no tratamento de distúrbios respiratórios por inalação |
| DE602005022499D1 (de) * | 2004-05-31 | 2010-09-02 | Almirall Sa | Kombinationen mit Antimuskarin-Wirkstoffen und PDE4-Hemmern |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| US20100150884A1 (en) * | 2005-02-10 | 2010-06-17 | Oncolys Biopharma Inc. | Anticancer Agent to Be Combined with Telomelysin |
| WO2007071313A2 (en) * | 2005-12-21 | 2007-06-28 | Meda Pharma Gmbh & Co Kg | Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases |
| EP1996179A2 (en) * | 2006-02-22 | 2008-12-03 | Valorisation-Recherche, Limited Partnership | Compositions for disorders associated with metachromatic cell activation |
| US8007790B2 (en) * | 2006-04-03 | 2011-08-30 | Stowers Institute For Medical Research | Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases |
| TWI436761B (zh) * | 2006-06-19 | 2014-05-11 | Otsuka Pharma Co Ltd | 使用噻唑衍生物之方法 |
| CN102764440A (zh) * | 2006-07-05 | 2012-11-07 | 奈科明有限责任公司 | 用于治疗炎症性肺部疾病的HMG-CoA还原酶抑制剂与磷酸二酯酶4抑制剂的组合 |
| WO2008010765A1 (en) | 2006-07-19 | 2008-01-24 | Astrazeneca Ab | Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity |
| ES2298049B1 (es) | 2006-07-21 | 2009-10-20 | Laboratorios Almirall S.A. | Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano. |
| JP5739616B2 (ja) * | 2007-02-21 | 2015-06-24 | アルミラル・ソシエダッド・アノニマＡｌｍｉｒａｌｌ， Ｓ．Ａ． | 新規方法 |
| CA2608561A1 (en) * | 2007-10-29 | 2009-04-29 | Carl Paluszkiewicz | Motorcycle wind deflector accessory support |
| EP2080523A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Compositions comprising an antimuscarinic and a long-acting beta-agonist |
| EP2080508A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Dry powder formulation comprising an anticholinergic drug |
| EP2100598A1 (en) * | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100599A1 (en) * | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2280708A1 (en) * | 2008-03-14 | 2011-02-09 | Otsuka Pharmaceutical Co., Ltd. | Mmp-2 and/or mmp-9 inhibitor |
| WO2009144494A1 (en) | 2008-05-27 | 2009-12-03 | Astrazeneca Ab | Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states |
| GB0814729D0 (en) * | 2008-08-12 | 2008-09-17 | Argenta Discovery Ltd | New combination |
| EP2156847A1 (en) * | 2008-08-19 | 2010-02-24 | Sanofi-Aventis | New combination of active ingredients containing an alpha1-antagonist and a PDE 4 inhibitor. |
| DK2400950T3 (da) | 2009-02-26 | 2019-07-29 | Glaxo Group Ltd | Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| WO2011011060A1 (en) | 2009-07-22 | 2011-01-27 | Puretech Ventures | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
| PT2600830T (pt) | 2010-08-03 | 2018-04-02 | Chiesi Farm Spa | Formulação de pó seco que compreende um inibidor de fosfodiesterase |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| AU2012266378B2 (en) | 2011-06-10 | 2017-03-02 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| RU2606121C2 (ru) | 2011-06-10 | 2017-01-10 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Соединения, обладающие антагонистической активностью в отношении мускариновых рецепторов и агонистической активностью в отношении бета2-адренорецепторов |
| DK3527199T3 (da) * | 2012-01-25 | 2022-10-24 | Chiesi Farm Spa | Tørpulverformulering omfattende et kortikosteroid og et beta-adrenergikum til indgivelse via inhalation |
| US9763965B2 (en) | 2012-04-13 | 2017-09-19 | Glaxosmithkline Intellectual Property Development Limited | Aggregate particles |
| US9156833B2 (en) | 2012-07-16 | 2015-10-13 | Barry University, Inc. | Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof |
| AU2013354043C1 (en) | 2012-12-06 | 2017-08-31 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| CN104854105B (zh) | 2012-12-06 | 2017-05-17 | 奇斯药制品公司 | 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物 |
| GB201222679D0 (en) | 2012-12-17 | 2013-01-30 | Glaxo Group Ltd | Pharmaceutical combination products |
| PL2968312T3 (pl) * | 2013-03-15 | 2018-08-31 | Verona Pharma Plc | Kombinacja leków |
| WO2015054101A1 (en) * | 2013-10-09 | 2015-04-16 | Icon Medical Corp. | Improved metal alloy for medical devices |
| BR112016010416B1 (pt) | 2013-11-15 | 2021-10-05 | Performance Polyamides, Sas | Composição de poliamida, e componente de metal |
| RU2685706C2 (ru) * | 2014-01-10 | 2019-04-23 | Эфиммьюн Лимитед | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением |
| TWI703138B (zh) | 2015-02-12 | 2020-09-01 | 義大利商吉斯藥品公司 | 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物 |
| AR104828A1 (es) | 2015-06-01 | 2017-08-16 | Chiesi Farm Spa | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO |
| WO2017093208A1 (en) | 2015-12-03 | 2017-06-08 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| CN108473437B (zh) * | 2016-01-08 | 2022-03-25 | 西伦制药公司 | 7-氮杂双环[2.2.1]庚烷衍生物的干粉吸入器组合物 |
| WO2018011090A1 (en) | 2016-07-13 | 2018-01-18 | Chiesi Farmaceutici S.P.A. | Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| EP3625232B1 (en) | 2017-05-19 | 2021-06-23 | Council of Scientific and Industrial Research | Substituted methanopyrido [2, 1-a]isoindolones as machr modulators for treating various associated pathophysiological conditions and process for preparation thereof |
| US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| CA3180743A1 (en) | 2018-09-28 | 2020-04-02 | Karuna Therapeutics, Inc. | Composition comprising xanomeline and trospium for treating disorders ameliorated by muscarinic receptor activation |
| EP3883634A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| EP4309722A2 (en) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| IT202000006442A1 (it) * | 2020-03-27 | 2021-09-27 | Genetic S P A | Budesonide 21-phosphate salts and pharmaceutical compositions containing the same |
| US11504332B2 (en) * | 2021-03-23 | 2022-11-22 | Vk Research Associates Inc. | Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof |
Family Cites Families (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1219606A (en) * | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
| FR2414044A1 (fr) * | 1978-01-10 | 1979-08-03 | Pharmindustrie | Nouveaux derives d'aza-1 bicyclo(2,2,2) octane, utilisables comme medicaments |
| IT7920688V0 (it) | 1979-02-05 | 1979-02-05 | Chiesi Paolo Parma | Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore. |
| EP0069715B1 (en) | 1981-07-08 | 1986-11-05 | Aktiebolaget Draco | Powder inhalator |
| FR2539135B1 (fr) * | 1983-01-11 | 1986-02-28 | Essilor Int | Hydrogels de polyurethane et procede de fabrication |
| US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
| GB8334494D0 (en) * | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
| FI69963C (fi) | 1984-10-04 | 1986-09-12 | Orion Yhtymae Oy | Doseringsanordning |
| US4675326A (en) * | 1985-05-08 | 1987-06-23 | Gabriel Amitai | Bisquaternary antidotes |
| US4843074A (en) * | 1988-05-17 | 1989-06-27 | Marion Laboratories, Inc. | 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts |
| DE3927170A1 (de) * | 1989-08-17 | 1991-02-21 | Boehringer Ingelheim Kg | Inhalator |
| US5290815A (en) * | 1989-09-07 | 1994-03-01 | Glaxo Group Limited | Treatment of inflammation and allergy |
| US5610163A (en) * | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
| IT1237118B (it) | 1989-10-27 | 1993-05-18 | Miat Spa | Inalatore multidose per farmaci in polvere. |
| US5201308A (en) | 1990-02-14 | 1993-04-13 | Newhouse Michael T | Powder inhaler |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
| GB9015522D0 (en) | 1990-07-13 | 1990-08-29 | Braithwaite Philip W | Inhaler |
| WO1992003175A1 (en) | 1990-08-11 | 1992-03-05 | Fisons Plc | Inhalation device |
| US5507281A (en) * | 1990-08-30 | 1996-04-16 | Boehringer Ingelheim Kg | Device for initiating a mechanical switching operation in synchronism with the breathing |
| DE4027391A1 (de) * | 1990-08-30 | 1992-03-12 | Boehringer Ingelheim Kg | Treibgasfreies inhalationsgeraet |
| DK0503031T3 (da) | 1990-09-26 | 1999-01-04 | Pharmachemie Bv | Inhalator med et reservoir til flere doser af et materiale, der skal inhaleres |
| GB9026025D0 (en) | 1990-11-29 | 1991-01-16 | Boehringer Ingelheim Kg | Inhalation device |
| US5290539A (en) * | 1990-12-21 | 1994-03-01 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
| DE4108393A1 (de) * | 1991-03-15 | 1992-09-17 | Boehringer Ingelheim Kg | Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| DE4239402A1 (de) * | 1992-11-24 | 1994-05-26 | Bayer Ag | Pulverinhalator |
| WO1994013262A1 (en) * | 1992-12-09 | 1994-06-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Stabilized medicinal aerosol solution formulations |
| CZ287848B6 (en) | 1992-12-18 | 2001-02-14 | Schering Corp | Inhalator of powder substances |
| GB9412434D0 (en) * | 1994-06-21 | 1994-08-10 | Inmos Ltd | Computer instruction compression |
| CA2217954C (en) | 1995-04-14 | 2005-02-15 | Glaxo Wellcome Inc. | Metered dose inhaler for salmeterol |
| DE69617431T2 (de) | 1995-06-21 | 2002-08-01 | Asta Medica Ag | Arzneipulverkartusche mit integrierter dosiereinrichtung, sowie pulverinhalator |
| DE19528145A1 (de) * | 1995-08-01 | 1997-02-06 | Boehringer Ingelheim Kg | Neue Arzneimittel und ihre Verwendung |
| DE19536902A1 (de) * | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
| US5846983A (en) * | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
| US6150415A (en) * | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
| US5885834A (en) * | 1996-09-30 | 1999-03-23 | Epstein; Paul M. | Antisense oligodeoxynucleotide against phosphodiesterase |
| US6495167B2 (en) * | 1997-03-20 | 2002-12-17 | Schering Corporation | Preparation of powder agglomerates |
| ITMI981671A1 (it) * | 1998-07-21 | 2000-01-21 | Zambon Spa | Derivati ftalazinici inibitori della fosfodisterasi 4 |
| EP1102579B1 (de) * | 1998-08-04 | 2003-03-19 | Jago Research Ag | Medizinische aerosolformulierungen |
| DE19847968A1 (de) * | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen |
| GB9902689D0 (en) * | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
| DE19921693A1 (de) * | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| GB9913083D0 (en) * | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| ES2165768B1 (es) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US7214687B2 (en) * | 1999-07-14 | 2007-05-08 | Almirall Ag | Quinuclidine derivatives and medicinal compositions containing the same |
| GB9928311D0 (en) * | 1999-11-30 | 2000-01-26 | Novartis Ag | Organic compounds |
| US6410563B1 (en) * | 1999-12-22 | 2002-06-25 | Merck Frosst Canada & Co. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| FR2803378B1 (fr) * | 1999-12-29 | 2004-03-19 | Valeo Climatisation | Echangeur de chaleur a tubes a plusieurs canaux, en particulier pour vehicule automobile |
| WO2001054728A1 (en) * | 2000-01-28 | 2001-08-02 | Asahi Kasei Kabushiki Kaisha | NOVEL REMEDIES WITH THE USE OF β3 AGONIST |
| AU2001239550A1 (en) * | 2000-03-23 | 2001-10-03 | Takeda Chemical Industries Ltd. | Furoisoquinoline derivatives, process for producing the same and use thereof |
| GB0008485D0 (en) * | 2000-04-07 | 2000-05-24 | Glaxo Group Ltd | Pharmaceutical compositions |
| GB0009605D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medicaments |
| GB0009606D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Therapeutic combinations |
| GB0009583D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
| GB0009592D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory combinations |
| SK286694B6 (sk) * | 2000-05-22 | 2009-03-05 | Chiesi Farmaceutici S.P.A. | Aerosólový farmaceutický prostriedok |
| US20020052312A1 (en) * | 2000-05-30 | 2002-05-02 | Reiss Theodore F. | Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists |
| WO2002000241A2 (en) * | 2000-06-28 | 2002-01-03 | Aventis Pharma S.A. | Compositions and methods for regulating the cell cycle using a ki gene or polypeptide |
| US6852728B2 (en) * | 2000-10-14 | 2005-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them |
| US6706726B2 (en) * | 2000-10-14 | 2004-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anticholinergics which may be used as medicaments as well as processes for preparing them |
| WO2002036106A2 (de) | 2000-10-31 | 2002-05-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue arzneimittelkompositionen auf der basis von anticholingergika und corticosteroiden |
| US20030158196A1 (en) * | 2002-02-16 | 2003-08-21 | Boehringer Ingelheim Pharma Gmbh Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
| US20020193393A1 (en) * | 2001-03-07 | 2002-12-19 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
| US6620438B2 (en) * | 2001-03-08 | 2003-09-16 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists |
| US20020122773A1 (en) * | 2000-12-20 | 2002-09-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and dopamine agonists |
| US20020151541A1 (en) * | 2000-10-31 | 2002-10-17 | Michel Pairet | Pharmaceutical compositions containing tiotropium salts and antihistamines and their use |
| US20020137764A1 (en) * | 2000-10-31 | 2002-09-26 | Karin Drechsel | Inhalable formulation of a solution containing a tiotropium salt |
| US7776315B2 (en) * | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
| US20020183292A1 (en) * | 2000-10-31 | 2002-12-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and corticosteroids |
| DE10062712A1 (de) * | 2000-12-15 | 2002-06-20 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden |
| US6608054B2 (en) * | 2001-03-20 | 2003-08-19 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics and endothelin antagonists |
| DE10056104A1 (de) * | 2000-11-13 | 2002-05-23 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols |
| US20020193392A1 (en) * | 2000-11-13 | 2002-12-19 | Christel Schmelzer | Pharmaceutical compositions based on tiotropium salts of salts of salmeterol |
| SK287414B6 (sk) * | 2000-12-28 | 2010-09-07 | Laboratorios Almirall, S.A. | Chinuklidínové deriváty a kompozície s ich obsahom |
| US20020179087A1 (en) * | 2001-02-01 | 2002-12-05 | Karl-Heinz Bozung | Pharmaceutical compositions containing an oxitropium salt and a betamimetic |
| US20020189610A1 (en) * | 2001-02-01 | 2002-12-19 | Karl-Heinz Bozung | Pharmaceutical compositions containing an ipratropium salt and a betamimetic |
| US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| US20030216329A1 (en) * | 2001-04-24 | 2003-11-20 | Robinson Cynthia B. | Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s) |
| MXPA03010791A (es) * | 2001-05-25 | 2004-03-02 | Boehringer Ingelheim Pharma | Combinacion de inhibidor de pde4 y tiotropio a sus derivados para tratamiento de enfermedades obstructivas de vias respiratorias y de otras enfermedades inflamatorias. |
| DE10130371A1 (de) * | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
| US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| US6919325B2 (en) * | 2001-09-14 | 2005-07-19 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts |
| US6974803B2 (en) * | 2001-12-06 | 2005-12-13 | Pfizer Inc | Pharmaceutical combination |
| US6790856B2 (en) * | 2002-01-31 | 2004-09-14 | Boehringer Ingelheim Pharma Kg | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments |
| GB0202635D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
| US6756508B2 (en) * | 2002-03-04 | 2004-06-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Cinnamic acid salts, processes for their preparation, and their use as medicaments |
| US7094788B2 (en) * | 2002-04-13 | 2006-08-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions |
| ES2206021B1 (es) * | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| ES2195785B1 (es) | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| CA2492121A1 (en) * | 2002-07-08 | 2004-01-15 | Ranbaxy Laboratories Limited | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
| US20040058950A1 (en) * | 2002-07-09 | 2004-03-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
| WO2004039968A1 (ja) * | 2002-10-30 | 2004-05-13 | Japan Science And Technology Agency | 骨髄由来の不死化樹状細胞株 |
| ES2211315B1 (es) | 2002-11-12 | 2005-10-16 | Almirall Prodesfarma, S.A. | Nuevos compuestos triciclicos. |
| EP1567136A1 (en) * | 2002-11-27 | 2005-08-31 | ALTANA Pharma AG | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia |
| ES2211344B1 (es) | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| PE20040950A1 (es) * | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| DE10307759B3 (de) * | 2003-02-19 | 2004-11-18 | Schering Ag | Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel |
| US20040184995A1 (en) * | 2003-03-17 | 2004-09-23 | Yamanouchi Pharmaceutical Co., Ltd. | Novel dry powder inhalation for lung-delivery and manufacturing method thereof |
| ATE384529T1 (de) * | 2003-03-28 | 2008-02-15 | Nycomed Gmbh | Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen |
| EP1610788A1 (en) * | 2003-03-28 | 2006-01-04 | ALTANA Pharma AG | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| US20050026887A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a steroid |
| PL1651270T3 (pl) * | 2003-07-29 | 2007-06-29 | Boehringer Ingelheim Int | Leki do inhalacji zawierające betamimetyki i środki przeciwcholinergiczne |
| US20050026948A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| US20050026886A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor |
| US20050025718A1 (en) * | 2003-07-31 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| EP1651224B1 (en) * | 2003-07-31 | 2011-10-05 | Boehringer Ingelheim International GmbH | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
| DE10347994A1 (de) * | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Wässrige Aerosol-Zubereitung |
| ES2232306B1 (es) | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| CN101518532A (zh) * | 2004-02-06 | 2009-09-02 | Meda制药有限及两合公司 | 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合 |
| PL1713473T3 (pl) * | 2004-02-06 | 2013-08-30 | Meda Pharma Gmbh & Co Kg | Kombinacja leków antycholinergicznych i glikokortykoidów do długotrwałego leczenia astmy i POChP |
| EP1718336B1 (en) * | 2004-02-06 | 2008-06-25 | MEDA Pharma GmbH & Co. KG | Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases |
| US7375935B2 (en) * | 2004-04-12 | 2008-05-20 | Leviton Manufacturing Co., Inc. | Ground fault circuit interrupter with enhanced radio frequency interference suppression |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| US20060189551A1 (en) * | 2004-10-04 | 2006-08-24 | Duke University | Combination therapies for fungal pathogens |
-
2004
- 2004-05-31 ES ES200401312A patent/ES2257152B1/es not_active Expired - Fee Related
-
2005
- 2005-05-31 US US11/628,522 patent/US20080045565A1/en not_active Abandoned
- 2005-05-31 US US11/628,521 patent/US20070232637A1/en not_active Abandoned
- 2005-05-31 DE DE602005013220T patent/DE602005013220D1/de active Active
- 2005-05-31 CH CH00085/06A patent/CH696962A5/fr unknown
- 2005-05-31 EP EP05751702A patent/EP1763369B1/en active Active
- 2005-05-31 ES ES10010080.9T patent/ES2505329T3/es active Active
- 2005-05-31 AT AT05751702T patent/ATE417627T1/de active
- 2005-05-31 MX MXPA06013847A patent/MXPA06013847A/es active IP Right Grant
- 2005-05-31 PE PE2005000613A patent/PE20060292A1/es not_active Application Discontinuation
- 2005-05-31 CN CNA2005800176934A patent/CN1960761A/zh active Pending
- 2005-05-31 AT AT07019644T patent/ATE474600T1/de active
- 2005-05-31 PT PT100100809T patent/PT2292267E/pt unknown
- 2005-05-31 RS RSP-2009/0045A patent/RS50717B/sr unknown
- 2005-05-31 CN CN201210251471.0A patent/CN102755321B/zh not_active Expired - Fee Related
- 2005-05-31 BE BE2005/0268A patent/BE1016608A5/fr active
- 2005-05-31 NZ NZ551668A patent/NZ551668A/en not_active IP Right Cessation
- 2005-05-31 PT PT05751702T patent/PT1763369E/pt unknown
- 2005-05-31 PE PE2008000713A patent/PE20081650A1/es active IP Right Grant
- 2005-05-31 JP JP2007513836A patent/JP4966192B2/ja not_active Expired - Fee Related
- 2005-05-31 FR FR0505473A patent/FR2870744B1/fr active Active
- 2005-05-31 TW TW094117908A patent/TWI404530B/zh active
- 2005-05-31 BR BRPI0511662A patent/BRPI0511662B8/pt active IP Right Grant
- 2005-05-31 ZA ZA200600261A patent/ZA200600261B/xx unknown
- 2005-05-31 ME MEP-2009-570A patent/ME02779B/me unknown
- 2005-05-31 PE PE2008000712A patent/PE20081649A1/es active IP Right Grant
- 2005-05-31 CA CA2569077A patent/CA2569077C/en not_active Expired - Fee Related
- 2005-05-31 RS RSP20140434 patent/RS53529B1/en unknown
- 2005-05-31 RS RS20090197A patent/RS50787B2/sr unknown
- 2005-05-31 AU AU2005247107A patent/AU2005247107B2/en not_active Ceased
- 2005-05-31 PT PT05750538T patent/PT1763368E/pt unknown
- 2005-05-31 CN CNA2005800176953A patent/CN1960762A/zh active Pending
- 2005-05-31 ES ES07019646T patent/ES2348680T3/es active Active
- 2005-05-31 UY UY28933A patent/UY28933A1/es not_active Application Discontinuation
- 2005-05-31 DE DE602005022497T patent/DE602005022497D1/de active Active
- 2005-05-31 UA UAA200612581A patent/UA89184C2/ru unknown
- 2005-05-31 EP EP05750538.0A patent/EP1763368B2/en active Active
- 2005-05-31 SI SI200530690T patent/SI1763368T2/sl unknown
- 2005-05-31 PL PL10010080T patent/PL2292267T3/pl unknown
- 2005-05-31 BR BRPI0511660-0A patent/BRPI0511660A/pt not_active IP Right Cessation
- 2005-05-31 NZ NZ551667A patent/NZ551667A/en not_active IP Right Cessation
- 2005-05-31 AT AT05750538T patent/ATE424847T1/de active
- 2005-05-31 MC MC2511A patent/MC200083A1/xx unknown
- 2005-05-31 US US11/141,169 patent/US20050267135A1/en not_active Abandoned
- 2005-05-31 NL NL1029151A patent/NL1029151C2/nl active Protection Beyond IP Right Term
- 2005-05-31 CN CN200580017685XA patent/CN1960759B/zh active Active
- 2005-05-31 DK DK05748688T patent/DK1765404T3/da active
- 2005-05-31 CN CNA2005800176949A patent/CN1972716A/zh active Pending
- 2005-05-31 CA CA2568566A patent/CA2568566C/en not_active Expired - Fee Related
- 2005-05-31 EP EP10010079A patent/EP2319538A3/en not_active Withdrawn
- 2005-05-31 SI SI200531114T patent/SI1891973T1/sl unknown
- 2005-05-31 ME MEP-2014-434A patent/ME02134B/me unknown
- 2005-05-31 DK DK05750538.0T patent/DK1763368T4/da active
- 2005-05-31 KR KR1020067025298A patent/KR101174677B1/ko active IP Right Grant
- 2005-05-31 GB GB0526502A patent/GB2419819B/en active Active
- 2005-05-31 DK DK05751702T patent/DK1763369T3/da active
- 2005-05-31 MY MYPI20052478A patent/MY142095A/en unknown
- 2005-05-31 KR KR1020137005271A patent/KR20130027586A/ko not_active Application Discontinuation
- 2005-05-31 CN CNA2005800176915A patent/CN1960760A/zh active Pending
- 2005-05-31 AU AU2005247103A patent/AU2005247103B2/en not_active Ceased
- 2005-05-31 ES ES200650034A patent/ES2293849B2/es active Active
- 2005-05-31 EP EP10003016A patent/EP2210613A1/en not_active Withdrawn
- 2005-05-31 ES ES05750538T patent/ES2322280T5/es active Active
- 2005-05-31 ME MEP-2009-369A patent/ME01680B/me unknown
- 2005-05-31 DK DK10010080.9T patent/DK2292267T3/da active
- 2005-05-31 ES ES05751702T patent/ES2318498T3/es active Active
- 2005-05-31 BR BRPI0511667-8A patent/BRPI0511667A/pt active Search and Examination
- 2005-05-31 EP EP05748688A patent/EP1765404B1/en active Active
- 2005-05-31 MX MXPA06013848A patent/MXPA06013848A/es active IP Right Grant
- 2005-05-31 PL PL05751702T patent/PL1763369T3/pl unknown
- 2005-05-31 EP EP07019644A patent/EP1891973B1/en active Active
- 2005-05-31 PT PT07019644T patent/PT1891973E/pt unknown
- 2005-05-31 WO PCT/EP2005/005840 patent/WO2005115466A1/en active Application Filing
- 2005-05-31 RU RU2006142331/15A patent/RU2373935C2/ru not_active IP Right Cessation
- 2005-05-31 BR BRPI0511669-4A patent/BRPI0511669A/pt not_active IP Right Cessation
- 2005-05-31 EP EP14171384.2A patent/EP2774623B1/en active Active
- 2005-05-31 PL PL05748688T patent/PL1765404T3/pl unknown
- 2005-05-31 SI SI200530611T patent/SI1763369T1/sl unknown
- 2005-05-31 EP EP08014859A patent/EP2002845A3/en not_active Withdrawn
- 2005-05-31 US US11/141,428 patent/US20050267078A1/en not_active Abandoned
- 2005-05-31 UA UAA200612575A patent/UA89181C2/ru unknown
- 2005-05-31 DK DK07019644.9T patent/DK1891973T3/da active
- 2005-05-31 LU LU91214A patent/LU91214B1/fr active Protection Beyond IP Right Term
- 2005-05-31 GR GR20050100269A patent/GR1006045B/el active IP Right Grant
- 2005-05-31 PL PL07019644T patent/PL1891973T3/pl unknown
- 2005-05-31 EP EP10010080.9A patent/EP2292267B1/en active Active
- 2005-05-31 ME MEP-2009-371A patent/ME01670B/me unknown
- 2005-05-31 ES ES07019644T patent/ES2348558T3/es active Active
- 2005-05-31 BR BRPI0511666-0A patent/BRPI0511666A/pt not_active IP Right Cessation
- 2005-05-31 SI SI200500163A patent/SI21784A/sl not_active IP Right Cessation
- 2005-05-31 WO PCT/EP2005/005841 patent/WO2005115467A1/en active Application Filing
- 2005-05-31 JP JP2007513835A patent/JP5133054B2/ja not_active Expired - Fee Related
- 2005-05-31 HU HU0600139A patent/HUP0600139A3/hu unknown
- 2005-05-31 PL PL379660A patent/PL379660A1/pl not_active Application Discontinuation
- 2005-05-31 AR ARP050102229A patent/AR049066A1/es unknown
- 2005-05-31 JP JP2007513837A patent/JP5049120B2/ja not_active Expired - Fee Related
- 2005-05-31 SI SI200531895T patent/SI2292267T1/sl unknown
- 2005-05-31 PL PL05750538T patent/PL1763368T5/pl unknown
- 2005-05-31 JP JP2007513839A patent/JP5032984B2/ja not_active Expired - Fee Related
- 2005-05-31 EP EP08014478A patent/EP2002843A3/en not_active Withdrawn
- 2005-05-31 US US11/628,523 patent/US20080051378A1/en not_active Abandoned
- 2005-05-31 IT IT001021A patent/ITMI20051021A1/it unknown
- 2005-05-31 WO PCT/EP2005/005836 patent/WO2005115462A1/en not_active Application Discontinuation
- 2005-05-31 CN CNA200580017692XA patent/CN101018566A/zh active Pending
- 2005-05-31 EP EP08014479A patent/EP2002844B1/en active Active
- 2005-05-31 KR KR1020067025295A patent/KR101256417B1/ko not_active IP Right Cessation
- 2005-05-31 UA UAA200612576A patent/UA89182C2/ru unknown
- 2005-05-31 UA UAA200612583A patent/UA89185C2/ru unknown
- 2005-05-31 EP EP09011129A patent/EP2138188A1/en not_active Withdrawn
- 2005-05-31 JP JP2007513838A patent/JP5107701B2/ja not_active Expired - Fee Related
- 2005-05-31 US US11/141,427 patent/US20050288266A1/en not_active Abandoned
- 2005-05-31 CN CN2011100241324A patent/CN102085373A/zh active Pending
- 2005-05-31 UA UAA200612580A patent/UA89183C2/ru unknown
- 2005-05-31 RS RSP-2010/0378A patent/RS51386B/en unknown
- 2005-05-31 CA CA002533061A patent/CA2533061C/en active Active
- 2005-05-31 JP JP2006508319A patent/JP4928258B2/ja active Active
- 2005-05-31 MX MXPA06004124A patent/MXPA06004124A/es active IP Right Grant
- 2005-05-31 NZ NZ544539A patent/NZ544539A/en unknown
- 2005-05-31 UA UAA200612584A patent/UA86976C2/ru unknown
- 2005-05-31 BR BRPI0511656-2A patent/BRPI0511656A/pt not_active IP Right Cessation
- 2005-05-31 RU RU2006147250A patent/RU2404771C3/ru active Protection Beyond IP Right Term
- 2005-05-31 EP EP14171380.0A patent/EP2774622B1/en active Active
- 2005-05-31 AU AU2005247108A patent/AU2005247108B2/en active Active
- 2005-05-31 EP EP05747758A patent/EP1761280A1/en not_active Withdrawn
- 2005-05-31 RU RU2006147268/15A patent/RU2385721C2/ru not_active IP Right Cessation
- 2005-05-31 DE DE602005011803T patent/DE602005011803D1/de active Active
-
2006
- 2006-03-14 US US11/375,308 patent/US20060154934A1/en not_active Abandoned
- 2006-04-18 US US11/405,888 patent/US20060205702A1/en not_active Abandoned
- 2006-04-21 US US11/409,157 patent/US20060189651A1/en not_active Abandoned
- 2006-11-07 HK HK06112215A patent/HK1090306A1/xx not_active IP Right Cessation
- 2006-11-28 NO NO20065479A patent/NO20065479L/no not_active Application Discontinuation
- 2006-11-28 NO NO20065482A patent/NO338621B1/no not_active IP Right Cessation
- 2006-11-28 EC EC2006007037A patent/ECSP067037A/es unknown
- 2006-11-28 EC EC2006007038A patent/ECSP067038A/es unknown
- 2006-11-28 NO NO20065477A patent/NO20065477L/no not_active Application Discontinuation
- 2006-11-28 EC EC2006007036A patent/ECSP067036A/es unknown
- 2006-11-28 NO NO20065476A patent/NO20065476L/no not_active Application Discontinuation
- 2006-11-28 EC EC2006007035A patent/ECSP067035A/es unknown
- 2006-11-28 NO NO20065483A patent/NO20065483L/no not_active Application Discontinuation
- 2006-11-28 EC EC2006007033A patent/ECSP067033A/es unknown
- 2006-11-28 EC EC2006007034A patent/ECSP067034A/es unknown
- 2006-11-28 NO NO20065478A patent/NO334337B1/no active Protection Beyond IP Right Term
- 2006-11-29 IL IL179689A patent/IL179689A/en not_active IP Right Cessation
- 2006-11-29 ZA ZA200609986A patent/ZA200609986B/en unknown
- 2006-11-29 ZA ZA200609990A patent/ZA200609990B/en unknown
- 2006-11-29 IL IL179687A patent/IL179687A/en active IP Right Grant
- 2006-11-29 ZA ZA200609987A patent/ZA200609987B/en unknown
- 2006-11-29 IL IL179684A patent/IL179684A/en not_active IP Right Cessation
- 2006-11-29 ZA ZA200609985A patent/ZA200609985B/xx unknown
- 2006-11-29 ZA ZA200609989A patent/ZA200609989B/xx unknown
-
2007
- 2007-03-23 US US11/726,982 patent/US20070167489A1/en not_active Abandoned
- 2007-03-26 HK HK07103198A patent/HK1095757A1/xx not_active IP Right Cessation
-
2008
- 2008-02-15 US US12/070,298 patent/US20080146603A1/en not_active Abandoned
- 2008-12-16 US US12/335,849 patent/US20090099148A1/en not_active Abandoned
- 2008-12-16 US US12/335,915 patent/US20090093503A1/en not_active Abandoned
- 2008-12-19 US US12/339,263 patent/US20090111785A1/en not_active Abandoned
-
2009
- 2009-02-20 HR HR20090107T patent/HRP20090107T3/xx unknown
- 2009-03-16 CY CY20091100290T patent/CY1108885T1/el unknown
- 2009-03-17 US US12/405,613 patent/US20090176751A1/en not_active Abandoned
- 2009-03-20 CY CY20091100315T patent/CY1108902T1/el unknown
- 2009-04-09 HR HRP20090215TT patent/HRP20090215T4/hr unknown
- 2009-05-13 HK HK09104362.3A patent/HK1125573A1/xx unknown
- 2009-06-09 CY CY20091100602T patent/CY1109139T1/el unknown
- 2009-10-28 US US12/607,409 patent/US20100048615A1/en not_active Abandoned
- 2009-10-28 US US12/607,429 patent/US20100048616A1/en not_active Abandoned
- 2009-11-12 US US12/616,960 patent/US20100056486A1/en not_active Abandoned
-
2010
- 2010-04-06 CY CY20101100311T patent/CY1109938T1/el unknown
- 2010-07-16 RU RU2010129940/15A patent/RU2465902C2/ru not_active IP Right Cessation
- 2010-09-03 HR HR20100489T patent/HRP20100489T1/hr unknown
- 2010-09-16 CY CY20101100844T patent/CY1110798T1/el unknown
- 2010-09-29 US US12/893,438 patent/US20110021476A1/en not_active Abandoned
- 2010-10-01 US US12/896,232 patent/US20110021478A1/en not_active Abandoned
- 2010-10-01 US US12/896,013 patent/US20110021477A1/en not_active Abandoned
-
2011
- 2011-03-22 CL CL2011000607A patent/CL2011000607A1/es unknown
- 2011-09-29 JP JP2011215066A patent/JP2012012407A/ja active Pending
- 2011-10-26 US US13/282,042 patent/US20120040943A1/en not_active Abandoned
- 2011-11-10 US US13/293,676 patent/US20120059031A1/en not_active Abandoned
- 2011-11-23 US US13/303,864 patent/US20120071452A1/en not_active Abandoned
- 2011-12-19 US US13/329,768 patent/US20120088743A1/en not_active Abandoned
-
2012
- 2012-03-02 US US13/411,003 patent/US20130035319A1/en not_active Abandoned
- 2012-07-06 JP JP2012152733A patent/JP5538485B2/ja not_active Expired - Fee Related
- 2012-08-02 US US13/565,413 patent/US20120302532A1/en not_active Abandoned
- 2012-08-17 US US13/588,106 patent/US20120309726A1/en not_active Abandoned
- 2012-08-17 US US13/588,124 patent/US20120309727A1/en not_active Abandoned
-
2013
- 2013-04-02 US US13/855,486 patent/US20140094442A1/en not_active Abandoned
- 2013-05-21 US US13/899,161 patent/US20130252928A1/en not_active Abandoned
- 2013-07-25 US US13/951,004 patent/US20130310354A1/en not_active Abandoned
-
2014
- 2014-01-29 US US14/167,809 patent/US20140148420A1/en not_active Abandoned
- 2014-06-16 US US14/305,701 patent/US20140296197A1/en not_active Abandoned
- 2014-08-28 US US14/471,819 patent/US20150202213A1/en not_active Abandoned
- 2014-09-11 HR HRP20140864TT patent/HRP20140864T1/hr unknown
- 2014-10-22 CY CY20141100869T patent/CY1115669T1/el unknown
- 2014-10-23 HK HK14110614.9A patent/HK1198120A1/xx unknown
- 2014-11-20 US US14/549,347 patent/US20150080359A1/en not_active Abandoned
-
2015
- 2015-02-19 NL NL300720C patent/NL300720I1/nl unknown
- 2015-02-27 HU HUS1500011C patent/HUS1500011I1/hu unknown
- 2015-02-27 NO NO2015007C patent/NO2015007I2/no not_active IP Right Cessation
- 2015-03-02 LT LTPA2015010C patent/LTC1763368I2/lt unknown
- 2015-03-03 CY CY2015006C patent/CY2015006I2/el unknown
- 2015-07-09 US US14/795,194 patent/US20150306079A1/en not_active Abandoned
- 2015-10-22 US US14/920,519 patent/US20160038470A1/en not_active Abandoned
-
2016
- 2016-03-24 US US15/080,475 patent/US20170049756A1/en not_active Abandoned
-
2017
- 2017-08-28 US US15/688,679 patent/US20180200234A1/en not_active Abandoned
-
2019
- 2019-02-07 US US16/269,705 patent/US20200009117A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008500987A5 (ja) | ||
| HRP20140864T1 (hr) | Kombinacije koje sadrže antimuskarinska sredstva i beta-adrenergiäśke agoniste | |
| US11000517B2 (en) | Dosage and formulation | |
| HRP20200298T1 (hr) | Pripravci za respiratorno davanje aktivnih sredstava i pripadajući postupci i sustavi | |
| EP2265258B1 (en) | Inhalation composition containing aclidinium for treatment of asthma | |
| MA39155A1 (fr) | Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol | |
| JP2009534387A5 (ja) | ||
| AU2013265167B2 (en) | Novel dosage and formulation | |
| DE03754425T1 (de) | Anwendungen die in Bezug stehen mit durch Wasser stabilisierte medizinische Aerosolformulierungen | |
| JP2006518382A5 (ja) | ||
| RU2009101317A (ru) | Способы применения производных тиазола | |
| RU2021104054A (ru) | Ингалятор отмеренных доз с распылением сжатым воздухом, содержащий забуференный фармацевтический состав | |
| RU2021101525A (ru) | Ингалятор отмеренных доз с распылением сжатым воздухом, содержащий забуференный фармацевтический состав |